 Mucinous epithelial ovarian cancer (mEOC) is a rare chemo-resistant subtype of ovarian cancer with distinct epidemiology, pathology and natural history.  mEOC can often masquerade as metastatic mucinous tumours from the gastrointestinal (GI) tract.  Molecularly, in contrast to high-grade serous ovarian cancer (HGSOC), mEOC are far less defined by p53 mutations and instead commonly harbour KRAS and HER 2 mutations.  The current gold standard of 1 st line platinum/taxane doublet chemotherapy, is more tailored towards HGSOC and generally ineffective for mEOC.  This review summarises the limited evidence for using GI style chemotherapeutic agents in treating mEOC and explores novel therapeutic possibilities such as targeting HER2, VEGF and Src.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Introduction
Epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy in developed nations. Amongst the various histotypes, mucinous epithelial ovarian cancers (mEOC) represent approximately 3% of EOC presentations and are generally classified as Type I (i.e. low grade) tumours. Alongside all other EOC subtypes, the cornerstone of therapeutic management for this disease traditionally involves surgical debulking (either primary or interval) in conjunction with platinum/taxane doublet chemotherapy delivered with either neoadjuvant or adjuvant intent [1] [2] [3] [4] [5] . However, mEOC embodies a disease entity with a distinct natural history, molecular biology, chemo-sensitivity and prognosis in comparison with the predominant high-grade serous (HGSOC) subtype [6] [7] [8] [9] . Alarmingly, the current gold standard of HGSOC chemotherapeutic management is still counterintuitively adopted for mEOC; a relatively chemoresistant disease [6] [7] [8] 10] . Hence, within the burgeoning era of personalised medicine, there is an urge to pursue a more refined approach in systemically managing mEOC. This may well involve learning lessons from treatment algorithms utilised in other malignancies, which share significant histopathological and molecular characteristics with this unique subtype [7, 8, 11] . The review herein presents numerous studies utilising such approaches in addition to outlining the key molecular drivers of mEOC which hold some promise in stratifying patients who would gain significant survival advantages with novel therapies.
Epidemiology
In comparison to HGSOC (70% EOCs), mEOC is a relatively rarer subtype which comprises 7-14% of all primary epithelial ovarian cancers in historical cohorts [12] . However, given the notorious difficulties in distinguishing true primary mEOC from metastatic mucinous carcinomas from the gastrointestinal (GI) tract, the actual prevalence of mEOC may be closer to 3% [9, 13, 14] . Invasive mEOC most commonly presents in women between 39 and 50 years old (range [15] . This middle-aged preponderance contrasts with the incidence of HGSOC which generally increases with age [16] . There also appears to be a clear aetiological discordance between HGSOC and mEOC. For example, HGSOC risk factors such as nuliparity, menarchal age, increased body mass index, oestrogen exposure, tubal sterilisation and lack of breastfeeding do not consistently correlate with mEOC prevalence [17] .
Similarly, smoking, which has no strong historical association with HGSOC, may be a significant risk factor for mEOC [17] . Whilst most ovarian cancers are diagnosed without family history, a positive history of mucinous cancer has been shown to dramatically increase the risk ratio of further cancers, particularly in comparison to EOC [17, 18] . A recent Danish population study observed an inverse relationship between statin use and mEOC incidence versus a neutral relationship between statin use and HGSOC incidence [19] . Furthermore, BRCA1 and BRCA2 oncogenes which increase lifetime risk of breast and other epithelial ovarian cancers (in particular HGSOC), has a negligible influence on mEOC risk [20] .
Despite sharing a common müllerian cell origin, the understanding of mEOC has evolved to the point where it must be considered a separate disease entity. In contrast to HGSOC, the vast majority (80%) of mEOC are diagnosed at an early stage [15] . Interestingly, stage I mEOC, where the management is primarily mandated by surgery alone, has a better prognosis than HGSOC [15, 21] . Moreover, retrospective evidence suggests that it is a reasonable option to offer women fertility sparing surgery for early stage mEOC [22] .
Conversely, advanced mEOC (stage III) typically has a significantly worse prognosis than HGSOC, with reported median survivals of 12-14 months versus 37-42 months respectively [9] . This is exemplified by the fact that in comparison to HGSOC, mEOC is more likely to present with particular adverse prognostic features such as parenchymal liver metastases.
However, paradoxically, advanced mEOC is also more likely to feature classically favourable prognostic feature such as limited peritoneal carcinomatosis, and higher likelihood of optimally debulked disease [6] . Nevertheless, from a therapeutic perspective, advanced mEOC is less chemoresponsive and subsequently has a worse progression free (PFS) and overall survival (OS) than other EOC subtypes [7] .
Histopathology
Differentiating primary ovarian mucinous tumour from metastatic mucinous tumour of gastrointestinal or other gynaecological origin is challenging. GI tract malignancies, particularly the large intestine, appendix, and pancreas are frequently identified in the ovary [23, 24] , with metastases from the biliary tract, stomach, cervix, breast and uterus also described [25, 26] . Pseudomyxoma peritonei, once considered a consequence of advanced mEOC, is now widely accepted as a result of metastatic appendiceal mucinous tumours [27] .
Furthermore, it is well documented that metastatic mucinous tumours from other organs can frequently masquerade as advanced primary mEOC. As metastatic cancers of GI origin generally have a worse prognosis than ovarian cancers, it is certainly possible that a proportion of patients labelled as late stage mEOC may have been misdiagnosed [9, 13, 14] , which accounts for the seemingly inferior outcomes synonymous with late stage mEOC. In a study by Zaino et al. [9] , 61% (27/44) of patients initially described as having a primary mEOC were eventually reclassified to be likely metastatic rather than primary mucinous ovarian tumours. Interestingly the median survival did not appear to differ significantly between the primary or metastatic cohorts. Additional studies have also described this pattern of reclassification after exhaustive review [14, 28] . Significantly, certain pathological differences are apparent between mucinous metastases and primary mEOC (Table 1) . Key diagnostic clues include bilaterality; a phenomenon apparent in >90% of metastatic tumours and a relatively rare presentation in primary cancers [14] . Additionally, tumour size > 10cm is much more likely to be of primary origin. These two factors influenced Seidman et al. [14] to devise an algorithm that correctly identified 90% of tumours as either primary tumours or metastases; a concept which has also been validated in subsequent studies [29, 30] .
In the instance of diffusely metastatic disease, distinguishing between primary mEOC and metastatic mucinous tumours from other primaries can be particularly complex. Within this sphere, immunohistochemistry (IHC) is an invaluable pathological tool (Table 2 ). Primary mEOC commonly shares positive IHC patterns for CK20, CEA, CA 19.9 and CDX2 with metastatic colorectal cancer (CRC) [32] . However, CK7 serves as a useful discriminator being diffusely positive in mEOC and predominantly negative in mucinous colorectal cancer (CRC) [32] . Nevertheless, a revision of the mucinous cancer algorithm by Maeda-Taniguchi et al. [28] has also found that combining serum biomarkers CA125 and CA19-9 further improved the positive predictive values of tumour classification. Other markers not commonly analysed that are frequently demonstrated in mucinous CRC include a-methyl acyl-CoAracemase, meprin a, guanylyl cyclase C, MUC2, dipeptidase 1 and -catenin; however these are currently of limited diagnostic use due to considerable overlap with other tumour types [32] . Moreover, a retrospective study of 500 ovarian cancer cases by Kobel et al. [33] found consistent differences in the expression of 20 out of 21 biomarkers when comparing various subtypes of EOC. This consolidates the notion of the deep heterogeneic nature of this disease and the necessity for each sub-type to be handled as separate disease entities, with unique prognostic and therapeutic paradigms [33] .
Intriguingly, the level of histological complexity also extends to hormone receptor expression. Historically, mEOC tumours were deemed less likely to express oestrogen and progesterone receptors (ER, PR) than HGSOC, but a recent paper challenges this notion, finding higher rates of ER and PR expression in mEOC (88% & 84%) vs. HGSOC (66% & 64%). However, there is a paucity of prospective evidence on the differential efficacy of endocrine therapy for mEOC vs. HGSOC [34] .
Molecular biology
Distinct differences in gene expression distinguish mEOC from other epithelial ovarian cancer subtypes. In general, mEOC appears to share many molecular biological characteristics with primary GI tumours (Table 3 ). In contrast to HGSOC, mEOC typically demonstrates overexpression of the K-RAS oncogene. Moreover, KRAS mutations are prevalent in 43-46% of mEOC, 30% mucinous CRC and 28% non-mucinous CRC (35) (36) (37) .
With respect to P53 mutations which represent the hallmark of HGSOC (approx. 96%) [35] , this is only limited to < 30% of mEOC cases [36] . However, a recent Australian study using whole genome sequencing of 24 tumours reported a surprisingly high rate of TP53 mutations (52%), again highlighting the heterogeneity of entities that are classified as mEOC [37] .
BRAF mutations, a well-established adverse prognostic marker in CRC, appears to be rare in mEOC, accounting for none of the mEOC samples assessed by Gemigani et al. [38] . This contrasts to BRAF mutations evident in 20% of mucinous CRC and 8% of non-mucinous CRC. APC mutations also vary significantly between these cancer types, from 9% in mEOC to 88% in non-mucinous CRC [11, 39, 40] . Furthermore, recent research has reviewed HER2 amplification in mEOC. Whilst relatively uncommon in EOC, HER2 overexpression rates up to 35% in mEOC have been documented [41] [42] [43] [44] [45] [46] [47].
With the advent of genome wide association studies (GWAS), there have been recent advances specific to mEOC within this realm. Kelemen et al. [57] evaluated 1644 patients with mEOC vs. 21693 controls and identified 3 new single nucleotide polymorphism (SNP) which were associated with mEOC risk at independent genomic loci. This consortium also used expression quantitative trait locus (eQTL) analysis to identify associations between candidate SNP variants and gene expression in both HGSOC and CRC tumours from the Cancer Genome Atlas. One of the susceptibility genes for mEOC, HOXD9, is an established high grade HGSOC susceptibility gene, indicating a possible shared role for this gene in oncogenesis of both distinct types of EOC. Another SNP identified was associated with mEOC risk and PAX8 expression in colorectal cancers but not HGSOC [57] .
Clinical management and pitfalls
The current standard of care for all EOC, regardless of histology, is defined by surgical debulking in early stage (Ia -Ib) disease; and adjuvant platinum/taxane doublet chemotherapy in addition to surgical debulking in more advanced disease (Ic-IIIc)[1-5].
However, whilst representing an efficacious strategy for the majority of ovarian cancers comprised mainly of HGSOCs, this does not directly translate to rarer subtypes such as mEOC.
As a reflection of its low prevalence, the landmark randomized control trials which established platinum/taxane as the 'gold standard' standard of care in the first-line management of EOC only comprised a small number of mEOC subjects (Table 4) .
Significantly, there has not been a sub-group analysis on the differential efficacy of treatment on patients with mEOC in these studies. Moreover, if such data was available, any conclusions would be limited by a lack of statistical power. As previously mentioned, mEOC is more likely to diagnosed at an earlier stage and lower grade compared with HGSOC [6, 7, 12] . Stage I mEOC has an excellent prognosis with 5 year survival of 90% with surgery alone, which is comparable if not superior to HGSOC [6, 8, 58] . Conversely, in the advanced disease setting, a number of studies have consistently demonstrated markedly inferior outcomes for mEOC compared with HGSOC, when treated with platinum-based chemotherapy both in the first-line, as well as the recurrent setting (table 5) .
In comparison with HGSOC, the poor prognosis of advanced mEOC is manifested by its' inherent aggressive biology (i.e. proclivity in visceral dissemination) and inferior response rates to platinum chemotherapy. Overall, the data would seem to support that relative chemoresistance is the major reason for inferior outcomes in advanced mEOC. In both in vitro and in vivo preclinical models, mEOC cell lines demonstrate intrinsic platinum resistance [65] . As outlined in Table 5 
Alternate chemotherapy algorithms
Due to the numerous pathological and molecular commonalities shared by mEOC and GI tumours, it has long been hypothesised that adopting standard GI treatment algorithms maybe more effective for mEOC than the current standard of care involving platinum/taxane based therapy.
Fluoropyrimidines
The thymidylate synthase inhibitor 5-fluorouracil (5FU) has long been the cornerstone of systemic therapy for CRC. A number of early phase II studies in the 1990s [66] [67] [68] [69] [70] [71] evaluated the role of 5FU with leucovorin as second line settings and beyond in advanced EOC with modest response rates ranging between 0 to 23%. The 5FU regimens selected differed widely between studies and hence variable efficacy is reported. Furthermore, these were predominantly small studies which did not specify the histological subtypes of EOC treated.
A more recent retrospective study [72] of 53 heavily pre-treated patients (>3 lines of previous therapy), treated with 5FU (600mg/m 2 weekly for 6/8 weeks) and leucovorin found a response rate by Rustin Criteria (CA 125 decline >50%) [73] of 25%. However, under 2%
(1/53) had mucinous histology, with the remainder being serous or endometrioid.
As an oral analogue of 5FU, capecitabine has equivalent efficacy to 5FU in a number of GI cancers [74] [75] [76] [77] . Capecitabine was evaluated in a phase I/II study of 14 platinum refractory ovarian cancer patients, showing a 25% response rate (1 CR, 2 PR) [78] . However, subsequently a larger multi-centre Italian phase II study (MITO 6), [79] evaluated capecitabine at 1250mg/m 2 q2-3weekly in 32 platinum refractory advanced EOC patients and found a disappointing response rate of 3.1%, with a median PFS of 68 days. However, there were no mEOC patients in this cohort.
Oxaliplatin
Oxaliplatin is a synthetic platinum agent with relative non cross-resistance in vitro with cisplatin or carboplatin [80] . In combination with 5FU/leucovorin, it represents the preferential first-line regimen in the management of CRC in both adjuvant [81] and metastatic [82] settings. With respect to EOC, phase II studies with single agent oxaliplatin have reported an overall response rate (ORR) of 5.6-17% and 42-46% with single agent oxaliplatin in platinum resistant and platinum sensitive disease respectively [83, 84] .
However there is still no clear data as to the specific efficacy of oxaliplatin monotherapy for mEOC patients.
5FU/Leucovorin & Oxaliplatin (FOLFOX)
Four studies have demonstrated reasonable efficacy with an acceptable toxicity profile of FOLFOX (5FU/leucovorin + oxaliplatin) in platinum resistant, heavily pre-treated EOC [85] [86] [87] [88] (Table 6) . Again, these studies were all in the second-line or beyond setting and included only a handful of mEOC patients, so it is difficult to draw conclusions. However there is in vitro and in vivo data to suggest that this could prove an effective regime in mEOC. Sato et al. found synergistic efficacy of 5FU with oxaliplatin in 4 of 5 mEOC cell lines, which were resistant to cisplatin and paclitaxel. Furthermore, the combination of oxaliplatin and 5FU
significantly prolonged survival in a mEOC murine xenograft model [89] .
Gemcitabine & Oxaliplatin
Several studies have also demonstrated the efficacy of oxaliplatin combined with gemcitabine (GEMOX) in the 2 nd line setting for platinum resistant ovarian cancer. Vici et al. [90] reported an ORR of 37% in 41 heavily pre-treated platinum resistant EOC patients, of which 7%
(3/41) were mEOC. Yuan et al. [91] also noted an ORR of 35% (bolus gemcitabine) to 43.2%
(infusional gemcitabine) with GEMOX in pre-treated ovarian cancer. 16 of the 64 patients in this cohort had mucinous histology, but it is unclear whether there was any differential efficacy in response to GEMOX with mEOC in comparison to other histologies.
Irinotecan
The topoisomerase I inhibitor, irinotecan, also has a well-established role in the systemic management of metastatic colorectal cancer [92] both as a single agent [93] 
mEOC specific clinical trials
In the GOG241 trial [99] , the GCIG Intergroup made an ambitious but ultimately unsuccessful attempt to conduct an mEOC specific trial to definitively answer the question of (Table 7) . Although this latter observation suggests a trend in superior PFS for bevacizumab, the limited number of participants precludes any meaningful conclusions being deduced from this trial. Interestingly, on specialist pathology review 17/36 patients were actually considered to have not primary mEOC [99] .
Another mEOC specific study follows on from the success of the oral combination fluoropyrimidine S1 in patients with various GI malignancies [100] [101] [102] [103] ; whereby a Japanese group has initiated a phase II trial of S1 plus oxaliplatin for mEOC [104] .
Targeted therapeutic approaches 8,1 VEGF inhibition
The monoclonal VEGF-A antibody, bevacizumab, has been shown to modestly improve OS in addition to chemotherapy in metastatic CRC in several meta-analyses [105] [106] [107] [108] , and is currently established within the standard armamentarium in first line management of this disease. The role for the bevacizumab in EOC is also evolving with two large phase III trials confirming improve PFS in addition to adjuvant chemotherapy following primary debulking surgery [109, 110] and in both the recurrent platinum sensitive [111] and resistant settings [112] . Significantly, recent subgroup analyses demonstrate that adjuvant bevacizumab confers an OS advantage for high-risk patients with suboptimally debulked disease [109, 110] . As with all aforementioned studies, the phase III bevacizumab EOC trials all included only a handful of mEOC patients. Consequently, a subgroup analysis has not been conducted to verify any specific efficacy associated with bevacizumab in mEOC patients.
Nevertheless, there have been case reports documenting the anecdotal efficacy of bevacizumab monotherapy in mucinous ovarian cancer of low malignant potential [113] and in pseudomyxoma peritonei [114] . Bevacizumab is also effective and safe in combination with oxaliplatin and docetaxel in the first-line setting, as demonstrated by an ORR of 58.6% in a phase II trial of 132 EOC patients [115] . However, only 3 mEOC patients were represented in this cohort.
EGFR monoclonal antibodies
Cetuximab has been evaluated in phase II studies as both monotherapy [116] , and in combination with platinum-based chemotherapy [117, 118] Again, it is unclear if any of these patients had mucinous histology [121] . Nevertheless, given the biological plausibility and encouraging early data, future studies involving the prospective use of cetuximab in KRAS wild type mEOC patients certainly merit consideration.
Anti-HER2 therapy
Anti-HER2 targeted therapy has been a major success story in the management of HER2 amplified breast cancer [122] [123] [124] . Trastuzumab (HER2 monoclonal antibody) also has proven efficacy in the management of HER2 positive gastric and gastro-oesophageal junction cancer as evidenced by the TOGA trial where its' combination with chemotherapy improved response rates from 34.5% to 47.3% and resulted in an OS benefit of 2.7 months (HR 0.74) [125] . However, HER2 overexpression is significantly less likely in mucinous gastric cancers compared with gastric cancers in general [126] . Combinatorial anti-HER 2 therapies with trastuzumab and lapatinib (HER 2 tyrosine kinase inhibitor) has also shown early promise in the small proportion of heavily pre-treated colorectal cancer patients with HER2 amplification in the HERACLES trial, with a response rate of 33.3% [127] .
In comparison with breast cancer, HER2 expression is relatively rare in EOC (11.4%) and targeted therapy with trastuzumab has subsequently garnered an ORR of 7% [128] Conversely, the HER2 expression in mEOC is significantly higher with a reported frequency II combinatorial study with lapatinib and topotecan failed to demonstrate meaningful benefit in platinum pre-treated EOC [131] . Notably, none of these patients had tumours overexpressing HER2 which would certainly support the negative results. Although there is a solitary case report of progressive mEOC treated successfully with dual HER2 inhibition with trastuzumab and lapatinib [132] , larger studies involving anti-HER 2 targeted therapy specific for HER2 amplified mEOC patients are certainly warranted.
Targeting Src and PI3K/Akt pathways
Another potential avenue for future research in mEOC therapy includes targeting Src kinase.
Src kinase is a non-receptor tyrosine kinase which is a convergence point for numerous oncogenic pathways [133] and has been implicated in mechanisms of oxaliplatin resistance in colorectal cancer [134] . In preclinical mEOC models, encouraging results have been achieved by targeting Src signaling with dasatinib [135] and KX-01; a novel Src inhibitor and antitubule agent, in synergy with oxaliplatin [136] .
The PI3K/AKT/MTOR pathway may also serve as a putative target in mEOC. Using a dual PI3K and mTOR inhibitor, Kudoh et al. were able to successfully suppress tumour growth in mEOC cell lines and xenografted murine models [137] .
Conclusions
Future strategies for the treatment of mEOC hinge on improved molecular understanding of this subtype. Ultimately, there is a dire need for more sophisticated therapies, which improve upon the efficacy witnessed with the current crude paradigm consisting of platinum/taxane doublets. Clearly, whilst there is good biological rationale with the trial of 'GI style' chemotherapy in mEOC, adopting this philosophy should be viewed with an element of caution. Unfortunately, although the investigators of the GOG241 study should be applauded for their attempts to investigate this concept; it demonstrates the immense difficulty in conducting a multicentre cooperative group study in a rare subtype. Furthermore, a direct translation of this approach maybe hindered by the fact that mEOC has more pathological and molecular characteristics in common with mucinous colorectal cancers [11] , as opposed to the more common non-mucinous counterparts which are generally more sensitive to the aforementioned chemotherapy regimes commonly used in CRC [138, 139] . While 'GI style' systemic chemotherapy may initially appear an intuitive notion, there is a paucity of evidence to substitute this for platinum/taxane doublet therapy in mEOC. Hence, from a practical perspective, until randomised trials confirm superior efficacy with this approach, current gold-standard EOC treatment algorithms should be adopted for mEOC patients. 
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